What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry
However, "stronger" also means stronger side effects, with discontinuation rates of 12-18% for retatrutide versus 5-7% for semaglutide
When combined with counseling, supportive care and psychotherapy, these medications are safe and effective
Establishes the baseline GLP-1 medication will work against, and reveals whether your current health makes you a good candidate.